Morphose
ActiveSummary
The computed 12-month bankruptcy probability of Morphose is 3.7% (moderate). The 2025 annual accounts show negative equity (-€55,345) and a net result of €422. Equity remains stable across the filed fiscal years (±1.6% per year). Its solvency ranks better than 6% of 21938 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
24-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 24 days late
2025
31-12
Financial
Back to profitnet €422
Net result €422 after 2 loss-making years.
31-12
Financial
Liquidity times 5current ratio 6.49
Current ratio from 1.43 to 6.49; short-term debt falls from €19,535 to €4,117.
26-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 57 days late
2024
11-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.